White House in firefighting mode after pause on J&J jabs

Published on April 14, 2021 11:08 AM AEST

White House in firefighting mode after pause on J&J jabs

Source: RajCreatives, Shutterstock

Summary

6 bloodclots reported among the US citizens after J&J vaccine

CDC, FDA analysing the data in clots

Australia has also been guarded about usage of AstraZeneca vaccine

The White House appeared to be in a firefighting mode – calming the nerves of the American people – after the vaccines from Johnson & Johnson (NYSE: JNJ) were put on a pause.

Representative image. © Silverv | Megapixl.com

The US healthcare officials – from Food and Drug Administration (FDA) and Centre for Disease Control (CDC) – recommended a temporary halt on the jabs from J&J as they are analysing the data after six women who took the vaccine saw rare and severe form of blood clotting.

“This announcement will not have a significant impact on our vaccination plan,” Jeff Zients, White House COVID-19 Response Coordinator said in a statement.

J&J’s vaccines make up only 5% of the American daily vaccine usage, according to Biden Administration official.

Mr Zients said that the administration has acquired sufficient stock of jabs from Moderna Inc (NASDAQ: MRNA) and Pfizer (NYSE: PFE) to vaccinate all the US citizens.

He claimed that administration has made available 25 million jabs of Moderna and Pfizer a week in the last few months. “In fact, this week we will make available 28 million doses of these vaccines,” Zients added.

Also read: Vaccine Updates From Different Nations: The UK, The US, NZ, CA, AU

Earlier, on Monday, Australia abandoned its target of vaccinating its entire population, as there have been fears surrounding the safety of the AstraZeneca Plc Vaccine (LON: AZN). There have been reports of similar blood clotting across continental Europe, after people were administered the AstraZeneca jabs.

Australia has, till now vaccinated 1.2 million of its 28 million population.

Also read: Australia begins COVID-19 inoculation with Pfizer-BioNTech’s vaccine

The shares of J&J corrected 1.34% after this on Wall Street and closed the day’s trade at US$ 159.48 apiece. However, the competitors shares started gaining after this: Moderna ended the day 7% higher, while Pfizer ended up 0.46% higher.

Furquan Moharkan

Author

Furquan Moharkan - Financial Journalist
377 Posts
Furquan Moharkan is journalist and an author with focus on banking and financial markets. He has also authored a book on banking. Before becoming a journalist, Furquan was an investment banker....
Follow Furquan Moharkan
Furquan Moharkan

Author

Furquan Moharkan - Financial Journalist
377 Posts
Furquan Moharkan is journalist and an author with focus on banking and financial markets. He has also authored a book on banking. Before becoming a journalist, Furquan was an investment banker....
Follow Furquan Moharkan

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.